HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma

Reuters

07-23

HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma

Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553724867"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553724867\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2553724867?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-23 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553724867","market":"fut","top_or_hot":-1,"title":"HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-23 20:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物醫藥B類股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL7Kc24N:1","article_id":"2553724867","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553724867","pubTimestamp":1753274241,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","BK1583":"高瓴概念","02142":"和铂医药-B"},"translate_title":"HBM Holdings Ltd.宣布长效抗TSLP抗体治疗哮喘的全球2期POLARIS试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":0.9},"content_text":"HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n    \n\n        Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}